Cure Vac's m RNA cancer vaccine
GPTKB entity
Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:activities |
stimulates immune response
|
| gptkbp:benefits |
personalized treatment
|
| gptkbp:clinical_trial |
gptkb:2020
gptkb:Cure_Vac_AG Phase 1 to be published overall survival evaluate safety and efficacy assessed for effectiveness multiple sites globally Phase 1, Phase 2 planned adaptive design approach |
| gptkbp:collaborations |
gptkb:Boehringer_Ingelheim
with pharmaceutical companies international research networks |
| gptkbp:committee |
composed of experts
|
| gptkbp:data_type |
adaptive immunity
|
| gptkbp:developed_by |
gptkb:Cure_Vac_AG
|
| gptkbp:dosage_form |
determined by trial protocol
|
| gptkbp:feedback |
collected during trials
|
| gptkbp:frequency |
varies by trial
|
| gptkbp:future_plans |
expand clinical trials
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cure Vac's m RNA cancer vaccine
|
| gptkbp:impact |
potential to change cancer treatment paradigm
|
| gptkbp:innovation |
gptkb:Company
advances in cancer immunotherapy |
| gptkbp:invention |
patents filed
|
| gptkbp:investment |
significant interest
high demand for cancer therapies |
| gptkbp:is_monitored_by |
ongoing throughout trials
|
| gptkbp:is_tested_for |
ongoing studies
|
| gptkbp:is_vulnerable_to |
m RNA-based platform
part of broader m RNA research |
| gptkbp:manager |
injection
|
| gptkbp:outcome |
tumor reduction
|
| gptkbp:partnerships |
various academic institutions
|
| gptkbp:platform |
Cure Vac's proprietary m RNA technology
|
| gptkbp:population |
various cancer types
|
| gptkbp:produced_by |
ongoing research
GMP compliant |
| gptkbp:publishes |
gptkb:literary_work
peer-reviewed journals |
| gptkbp:receives_funding_from |
public and private investments
grants and investments |
| gptkbp:recruitment |
ongoing for trials
|
| gptkbp:regulatory_body |
FDA approval process
|
| gptkbp:regulatory_compliance |
under investigation
|
| gptkbp:research |
preliminary results available
focused on m RNA technology |
| gptkbp:research_areas |
immuno-oncology
novel immunotherapy |
| gptkbp:research_focus |
oncology
|
| gptkbp:safety_features |
under evaluation
|
| gptkbp:scientific_goals |
improve efficacy and safety
|
| gptkbp:side_effect |
under investigation
|
| gptkbp:student_enrollment |
specific criteria apply
|
| gptkbp:supply_chain |
established for production
|
| gptkbp:targets |
gptkb:healthcare_organization
tumor-associated antigens |
| gptkbp:technology |
messenger RNA technology
|
| gptkbp:treatment |
monitored during trials
|
| gptkbp:bfsParent |
gptkb:Cure_Vac_AG
|
| gptkbp:bfsLayer |
4
|